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esponsibility of Xi'aAbstract A new ultra-performance liquid chromatography–electrospray ionization mass spectrometry (UPLC–
MS/ESI) method for simultaneous determination of venlafaxine (VEN) and its metabolite O-desmethyl-
venlafaxine (ODV) in rat plasma has been developed and validated using Venlafaxine d6 as the internal standard.
The compounds and internal standard were extracted from plasma by solid phase extraction. The UPLC
separation of the analytes was performed on ACQUITY UPLCs BEH Shield RP18 (1.7 mm, 100 mm
2.1 mm) column, using isocratic elution with mobile phase constituted of water (containing 2 mM ammonium
acetate): acetonitrile (20:80, v/v) at a ﬂow rate of 0.3 mL/min. All of the analytes were eluted within 1.5 min. The
compounds were ionized in the electrospray ionization (ESI) ion source of the mass spectrometer, operating in
multiple reaction monitoring (MRM) and positive ion mode. The precursor to product ion transitions monitored
for VEN, ODV and Venlafaxine d6 were m/z 278.3-121.08, 264.2-107.1 and 284.4-121.0, respectively.
The developed and validated method was used for the pharmacokinetic study of VEN in rats.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Else
2
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n Jiaotong University.1. Introduction
Venlafaxine (VEN), chemical structure 1-[2-(dimethylamino)-
1-(4-methoxy-phenyl)ethyl] cyclohexanol hydrochloride, is a
new antidepressant, which selectively inhibits re-uptake of nor-
epinephrine and serotonin, and slightly inhibits re-uptake of
dopamine, without signiﬁcant afﬁnity for muscarinic, histaminer-
gic or adrenergic receptors [1]. In humans VEN is metabolized
into two minor metabolites, N-desmethylvenlafaxine (NDV), N,O-
didesmethylvenlafaxine (DDV), and the major active metabolite,
O-desmethylvenlafaxine (ODV) which presents an activity proﬁlevier B.V. All rights reserved.
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ODV is controlled by CYP2D6, CYP2C19 and CYP2C9, with
estimated contributions of 89%, 10% and 1%, respectively [2–6].
There are several published methods for the determination of both
VEN and ODV in the biological matrix including CE, GC and
HPLC [7–9]. The reported HPLC method, using HPLC coupled
with mass spectrometry or coulometric detection, has high
sensitivity by using the solid-phase exaction (SPE) [9,10], while
others using ﬂuorescence or UV detection have low sensitivity or
long analysis time (410 min) [11–14]. The reported ultra-
performance liquid chromatography–electrospray ionization mass
spectrometry (UPLC–MS/ESI) [15] has a disadvantage of using
diethylether which is toxic and ﬂammable and uses high plasma
aliquot volume for sample preparation.
The aim of the present study is to establish a simple, rapid
and accurate UPLC–MS/ESI method for the measurement of VEN
and ODV in pharmacokinetic samples.2. Experimental
2.1. Equipments and reagents
A system of UPLC with a Micro mass ZQ mass spectrometer
(Wythenshawe, Manchester, UK) with mass-selective detector
equipped with an electrospray ionization (ESI) ion source was
used. Lenovo Workstation and MassLynx 4.1 software were
utilized. Venlafaxine, O-desmethylvenlafaxine and VenlafaxineFig. 1 Chemical structure of each compound: Venlafaxine (VEN),
O-desmethylvenlafaxine (ODV) and Venlafaxine d6.d6 were obtained from Sigma Aldrich. The structures of these
compounds are presented in Fig. 1.
MS grade reagents (methanol, acetontritile) and diethylether
were purchased from Merck, India. Triple distilled water was
prepared by a laboratory puriﬁcation system.
2.2. Standard and working solutions
The primary stock solutions of VEN (2 mg/mL), ODV (2 mg/mL),
and Venlafaxine d6 (1 mg/mL) were prepared by dissolving
appropriate amounts of pure substance in methanol. Working
solutions were obtained by diluting the stock solutions with
methanol. All the standard solutions were stored at 41 C. Routine
daily calibration curves were prepared in drug-free plasma.
Appropriate volumes of working solution and drug-free rat plasma
were added to each test tube. Final concentrations were 10, 25, 50,
100, 250, 500, 1000 and 2000 ng/mL for VEN and ODV. Quality
control (QC) samples, which were run in each assay, were pre-
pared in the same way.
2.3. Chromatographic conditions
Chromatographic separation of the analytes was performed on
ACQUITY UPLCs BEH Shield RP18 (1.7 mm, 100 mm 2.1
mm) column with column temperature 35 1C. The mobile phase
consisted of water (containing 2 mM ammonium acetate) and
acetonitrile (20:80, v/v) at a ﬂow rate of 0.3 mL/min.
2.4. Mass spectrometric conditions
For optimization of MS parameters 500 ng/mL of each analyte was
prepared in methanol. Argon was used as collision gas and
nitrogen as nebulizer gas. The compounds were ionized in the
positive electrospray ionization ion source (ESI+) of the mass-
spectrometer. The product ion spectrum (MS–MS) was generated
under optimized conditions to identify the prominent product ions
of the analytes. Multiple reaction monitoring (MRM) mode was
used for quantitation of each analyte depicted in Table 1.
2.5. Sample preparation
Sample preparation involved a simple solid phase extraction with
OASIS HLB (Hydrophilic lipophilic balance) cartridges. Twenty
microliters internal standard working solution (Venlafaxine d6,
50 mg/mL) was added to 300 mL aliquots of blank/spiked plasma
and vortexed. The cartridges were conditioned with methanol
(1 mL) and equilibrated with de-ionized water (1 mL). The
prepared samples were then loaded onto cartridges and theTable 1 Optimized MS/MS parameters.
Analyte Parent
ion
Product
ion
Cone
voltage
(V)
Collision
voltage
(V)
Capillary
voltage
(kV)
VEN 278.3 121.1 27 24 3.50
ODV 264.2 107.1 26 24 3.50
Venlafaxine
d6
284.4 121.0 12 42 3.50
S.K. Dubey et al.468cartridges were washed with 5% methanol (1 mL) and ﬁnally
eluted with methanol (1 mL). The eluates were evaporated to
dryness at 401 C under N2 gas. Residues were then reconstituted in
200 μL of mobile phase. Seven microliters of the solution was
injected for analysis through the auto-injector.
2.6. Method validation
The method was validated in terms of linearity, speciﬁcity and
selectivity, lower limit of detection (LOD) and lower limit of
quantiﬁcation (LLOQ), recovery, matrix effect, accuracy, precision
and stability. These parameters determined were carried out in six
replicates at low, medium and high concentration levels.
2.6.1. Linearity
Biological samples were quantiﬁed using the ratio of peak area of
VEN, ODV to that of internal standard. The calibration curves
were established through a linear least-squares regression with a
weighing factor of 1/C2, where C is the concentration of the
calibration standards. Coefﬁcients of correlations (r) were required
to be 0.99 or better. Concentration in the quality control was
quantiﬁed from the regression equation.
2.6.2. Speciﬁcity and selectivity
Interference in biological matrix arises from a number of endo-
genous sources (analyte, metabolite, degradation products occur-
ring in biological ﬂuids) and exogenous sources. The selectivity of
this method was investigated by analyzing six individual blank
plasma samples. Each blank sample was tested for interferences
using the proposed extraction procedure and LC–MS/MS
conditions.
2.6.3. LOD and LLOQ
The LODs for VEN and ODV were deﬁned as the drug
concentration in the plasma after the sample preparation method
that corresponds to three times the baseline noise S/N≥3. The
LLOQ was deﬁned as the concentration of the sample that can be
quantiﬁed with o20% deviation (S/N≥10).
2.6.4. Recovery
The percentage recovery of VEN, ODV and internal standard
was determined by measuring the mean peak area response of
six replicates of extracted QC samples at low, middle and high
levels against the mean peak area response of six replicates of
aqueous (unextracted) QC samples at concentrations representing
100% extraction of QC samples at low, middle and high
concentrations.
2.6.5. Matrix effect
Matrix effect is due to co-elution of some endogenous components
present in biological samples. These components may not give a
signal in MRM of the starget analyte, but can certainly decrease or
increase the response of the analyte dramatically to affect the
sensitivity, accuracy and precision of the method. Thus assessment
of matrix effect constitutes an important and integral part of
validation for quantitative LC–MS/MS method. To evaluate the
matrix effect, chromatographic peak areas of VEN, ODV from the
spike-after preparation samples were compared to those of the neat
standards at the QC concentrations.2.6.6. Accuracy and precision
The precision and accuracy of the method were assessed by intra-
and inter-day validation. The intra- and inter-day accuracy and
precision were determined by determining the concentrations of
VEN and ODV in plasma in six replicates of QC samples for three
separate batches. Precision was expressed as % CV.
2.6.7. Stability
Stability experiments were performed to evaluate stabilities of the
analytes in plasma samples under different storage and processing
conditions. All stability exercises were assessed by analyzing six
replicates of stability samples at low (LQC) and high quality
control (HQC) levels against freshly spiked calibration standards
and comparing with freshly spiked six replicates of samples at
LQC and HQC levels. Freeze–thaw stability of spiked plasma
samples was determined after three freeze–thaw cycles. Each cycle
consisted of removing the samples from the freezer, thawing them
unassisted to room temperature and keeping at room temperature
for 2 h and re-freezing at −501 C. Bench top stability evaluation
involved analysis of stability samples, which had been kept at
room temperature for a period of 7.5 h. Post preparative stability
involved analysis of stability samples, which were kept in a
refrigerator for 24 h. Stock solution stability was determined by
storing stability stock solutions in a refrigerator between 1 and
10 1C. After 10 days fresh stocks were prepared. A dilution with
the same concentration from each of the stability and fresh stocks
was prepared and six replicate injections were given. Short term
stability of stock dilution was determined by keeping stability
stock dilution at room temperature for 9 h and comparing it with
fresh stock dilution made from the same stock.
2.7. Pharmacokinetics of venlafaxine in rats
Seven healthy male Wistar strain rats weighing 180–220 g were used
in the study. An oral dose of venlafaxine 30 mg/kg was given to each
rat. The study was done for 24 h and the blood samples were drawn at
0.25, 0.5, 1, 2, 3, 6, 8, 12, 16 and 24 h after administration of drug.
Blood samples were collected in tubes containing ethylenediaminete-
traacetic acid (EDTA) as anticoagulant and centrifuged at 12,000 rpm
for 30 min at 51 C. The resulting plasma samples were stored at
−20 1C until analysis. The plasma samples were extracted by HLB
cartridges as described above and analyzed for VEN and ODV.
Different pharmacokinetic parameters were determined using Win-
Nonlin software.3. Results and discussion
3.1. UPLC–MS/ESI
The column temperature was 35 1C in order to reduce pressure of
column and improve resolution. Seven microliters of reconstituted
solution was injected for analysis in order to improve the
sensitivity. The UPLC–MS/ESI in the MRM mode provided a
highly selective method for the determination of VEN and ODV.
The retention times of ODV and VEN were approximately 0.83
and 0.93 min, respectively.
Compared with the published methods (the chromatographic
run was as long as 10–20 min) [16–18], the run time of this
method was shorter, i.e., complete elution was obtained in less
than 1.5 min. The chromatograms of VEN, ODV and Venlafaxine
d6 are depicted in Fig. 2.
Table 2 Absolute recoveries of VEN and ODV from rat
plasma.
Concentration (ng/mL) Absolute recovery (% mean7SD,
n¼6)
VEN ODV
20 (LQC) 78.472.6 76.472.4
400 (MQC) 82.676.7 80.675.8
1600 (HQC) 90.672.2 88.672.3
Fig. 2 Representative chromatograms of (A) VEN, (B) ODV and (C) Venlafaxine d6.
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3.2.1. Linearity and calibration standards
The concentration ranges were 10–2000 ng/mL for VEN and
ODV. The area ratio of each analyte to internal standard was well
related to the concentration. The data were based on three
replicates of an eight-point calibration curve and the linear
relationships were described by the following equations:
VEN : y¼ 0:0051xþ 0:00084; R2 ¼ 0:993
ODV : y¼ 0:0020xþ 0:01219; R2 ¼ 0:992
3.2.2. Speciﬁcity and selectivity
Chromatograms of six batches of control drug-free plasma
contained no co-eluting peak 420% of analyte area at LLOQ
level and no co-eluting peaks 45% of the area of internalstandard. There was no cross interference between analytes after
subjecting individual analytes. Representative chromatograms of
extracted VEN and ODV are shown in Fig. 2. The retention times
of both analytes and IS showed less variability, with a relative
standard deviation well within the acceptance limit of 5%.3.2.3. LOD and LLOQ
The LOD demonstrated that both VEN and ODV gave an S/N
ratio ≥3 of 2.66 ng/mL and 2.78 ng/mL respectively. The LLOQ
was 7.98 ng/mL for VEN and 8.34 ng/mL for ODV.3.2.4. Recovery
The extraction recovery was determined at three concentrations of
20, 400 and 1600 ng/mL as described in Table 2.
The percentage recovery of Venlafaxine d6 acid was deter-
mined by measuring the mean peak area response of Venlafaxine
d6 acid in extracted QC samples (MQC) against the mean peak
area response of aqueous (unextracted) internal standards solution
at a concentration representing 100% extraction of internal
standards in MQC samples. The recovery of Venlafaxine d6
was 88.8%.3.2.5. Accuracy and precision
The accuracy of the assay was deﬁned as the absolute value of
the calculated mean concentration of the QC sample to their
respective nominal values, expressed as percentage. The precision
of the assay was measured by the percent coefﬁcient of variation at
concentrations of LQC. MQC and HQC levels. The results are
presented in Table 3.
S.K. Dubey et al.4703.2.6. Stability
Analytes were stable in plasma for three freeze–thaw cycles.
Bench top stability for analytes was established for 7.5 h. Post
preparative stability indicated samples were stable for 24 h
after processing. The results of the stability exercises mentioned
above are given in Table 4. The stock solutions of VEN and
ODV were found to be stable for 10 days when stored in the
refrigerator (1–101 C). The percentage stability values of the stock
solutions for VEN and ODV were 106.3% and 94.2% respectively.
Short-term stability for VEN and ODV stock dilutions was
established for 9 h at room temperature. The stability values of the
stock dilutions for VEN and ODV were 98.1% and 97.7%
respectively. The precision was 0.8% for stability and 0.7% for
fresh dilutions for VEN. The precision was 1.2% for stability and
0.8% for fresh dilutions for ODV.3.3. Pharmacokinetic application
This validated UPLC–MS/ESI method was successfully applied to
a pharmacokinetic study, for simultaneous determination of VEN
and its active metabolite following oral administration of 30 mg/kg
venlafaxine hydrochloride in rats. The mean plasma concentra-
tion–time curve of VEN and ODV in single dose study is shown in
Fig. 3. The pharmacokinetic parameters of VEN and ODV are
given in Table 5. By observing the pharmacokinetic parameters,
the elimination half lives of VEN and ODV were comparable;
plasma clearance and volume of distribution of VEN and ODV are
high and similar. Based on Tmax value, VEN gets absorbed and
metabolized into ODV rapidly. Based on Cmax and AUC values itTable 4 Stability of VEN and ODV in rat plasma.
Parameters Concentration (ng/m
Bench top stability (for 7.50 h) 20 (LQC)
1600 (HQC)
Freeze–thaw stability (for three cycles) 20 (LQC)
1600 (HQC)
Post-processing refrigerator stability (for 24 h) 20 (LQC)
1600 (HQC)
Table 3 Accuracy (% basis) and precision (%RSD) of
analytes.
Analyte Concentration
(ng/mL)
Accuracy
(% basis)
Precision
(% RSD)
Intra-
day
Inter-
day
Intra-
day
Inter-
day
VEN 20 (LQC) 2.52 4.26 3.26 4.74
400 (MQC) 5.25 5.20 4.52 5.25
1600 (HQC) 3.55 3.80 2.20 3.86
ODV 20 (LQC) 5.06 6.28 5.25 5.10
400 (MQC) 3.54 4.75 4.25 2.06
1600 (HQC) 4.25 3.86 6.25 7.25is evident that exposure to ODV was less than VEN when
compared to humans; this might be due to conversion of more
VEN into cis-1,4-dihydroxycyclohexyl venlafaxine (major meta-
bolite in rats) or more formed ODV is metabolized further. Since
metabolism of VEN into ODV is dose dependent (saturation
kinetics), a higher dose (30 mg/kg) of VEN also leads to less
exposure of ODV when compared to VEN.4. Conclusion
This method had a suitable limit of quantiﬁcation along with the
very short retention time of 1.5 min which can be useful inL) VEN ODV
CV (%) % Nominal CV (%) % Nominal
1.2 103.2 1.5 103.2
1.5 101.5 1.1 98.5
1.1 102.5 1.3 105.2
1.6 105.4 0.8 101.5
1.5 102.9 0.9 106.2
1.8 99.2 1.6 101.5
Fig. 3 Plasma concentration–time proﬁle of VEN and ODV after oral
administration of 30 mg/kg of venlafaxine hydrochloride in rats.
Table 5 Pharmacokinetic parameters of VEN and ODV.
Parameters VEN ODV
Tmax (h) 0.5 1.0
Cmax (mg/mL) 1.48 0.47
AUC (mg h/mL) 2.92 2.33
Vd (L/kg) 185.58 –
Cl (L/h/kg) 41.03 –
t1/2 (h) 3.13 2.59
Determination of venlafaxine and its metabolite by UPLC–MS method 471analyzing many samples in a single day which is the most
advantageous aspect in comparison to other analysis techniques
available in published literature. This method employs a very
simple cost effective sample preparation technique as well as very
less injection volume (7 μL) resulting in high throughput bioana-
lysis technique. The method had advantage over problems of poor
chromatography, questionable uncharacterized peak, tedious
extraction steps, and high injection load. Our research thus
conﬁdently demonstrates for the ﬁrst time a simple, robust and
high throughput method requiring less than 1.5 min to run each
sample. Thus, as the pace of drug development quickens, we
cannot ignore the potential for our method application nor the time
saving which can present thus encouraging clinical and explora-
tory studies for the best possible antidepressant agents.Animal rights
The institutional and international guide for the care and use of
laboratory animals was followed. See the experimental part for
details.
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